Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.

Related Keywords

Stephenj Freedland , , Department Of Urology , Research In Cancer , Samuel Oschin Comprehensive Cancer Institute , Integrated Research , Law Families Chair ,